bluuebunny/crossref_metadata_2025_split huggingface dataset:
Exploring outcomes in hospitalized patients with COVID-19 based on nutritional status: Comparing those with and without a cancer diagnosis.
Authors: Bhinder Muhammad Mujtaba , Davis Elaine A. , Welch Christine A. , Kamran Amir Shahzad 
Published: June 2024

e23068 Background: This study explores how nutritional status impacts COVID-19 outcomes, particularly in patients with cancer. Obesity is known to heighten risk of adult respiratory distress syndrome in COVID-19, malnutrition and its associated effects related to the immune response, respiratory compromise, debility, and other adverse outcomes has not been well defined in this patient population. Methods: In this retrospective cohort study, we examined data from the Charleston Area Medical Center’s (CAMC) COVID-19 Registry, involving 5,479 adult, symptomatic, PCR-positive COVID-19 hospitalized patients (3/1/20 to 1/20/24). Low nutritional status (LNS) was defined as Body Mass Index (BMI) < 18.5 kg/m² or serum albumin < 3.5g/dL). Demographics, comorbidities, lab values, treatments, and outcomes were assessed. Propensity score matching (3:1) non-cancer patients vs those with an active cancer diagnosis was undertaken using sex, age, and BMI. SAS 9.4 was utilized for the analysis. The groups were compared using Chi-square/Fisher’s Exact tests for categorical variables and t-tests for continuous variables. Multivariate analysis was utilized to determine predictors of adverse outcomes. Results: A cohort of 1,146 non-cancer and 382 active cancer patients were included in the study. The LNS subgroup had a higher frequency of active cancer (29.2% vs 19.3%, p < 0.001), higher rates of diabetes (27.0% vs17.8%, p = 0.03) and chronic kidney disease (18.8% vs 11.7%, p = 0.02). They had greater frequencies of abnormal ferritin levels (57.8% vs 42.7%, p < 0.001), CRP levels > 3 mg/L (96.6% vs 90.3%, p < 0.001), and elevated procalcitonin levels > 0.05 ng/mL (71.2% vs 50.1%, p < 0.001). LNS patients had a higher mortality rate (22.3% vs 9.7%, p < 0.001), a higher need for mechanical ventilation (19.3% vs 9.5%, p < 0.001), and intensive care unit (ICU) admission (35.7% vs 19.5%, p < 0.001. Predictors of mortality included LNS (OR = 2.2, 95%CI [1.5-3.2], p < 0.001), an active cancer diagnosis (OR = 1.7, 95% CI [1.2-2.6], p = 0.003), chronic kidney disease (OR = 1.8 95%CI [1.3-2.5], p = 0.004) and concurrent bacterial pneumonia (OR = 4.9 95%CI [3.3-7.2], p < 0.001). Conclusions: In patients with COVID-19, those with LNS had higher rates of co-morbid conditions including active cancer, higher rates of elevated inflammatory markers, mechanical ventilation, ICU admission, and mortality. Predictors of mortality included concurrent bacterial pneumonia, cancer diagnosis and chronic kidney disease, with LNS increasing the risk of mortality by more than two-fold. These results support the recommendation of early nutritional assessment and a multi-disciplinary approach to aggressive nutritional support in the COVID-19 patient population particularly in those with a concurrent high-risk condition such as cancer.
Influence of aging, comorbidities, and chemotherapy on dementia in patients with metastatic cancer.
Authors: Shour Abdul Rahman , Rhodes Heather X. , Wen Zhi , Anguzu Ronald , Sheku Tejan Yusuf , N’jai Alhaji U. , Dedo Sika A. , Edet Precious Patrick , Puthoff David , Onitilo Adedayo A. 
Published: June 2024

e23097 Background: Studies highlight cognitive decline in cancer survivors, exploring treatment-linked neurodegeneration risks. Yet, the effects of aging (age), comorbidities, and chemotherapy on dementia in metastatic patients are unclear. Methods: US Trauma Quality Program (2017-2019) for 17,940 metastatic cancer patients was analyzed. Our outcome was dementia diagnosis in metastatic cancer patients (no/yes). Independent variables were patient’s age (younger adults aged 18-55 years and seniors ≥56 years), any comorbid condition (yes/no), and received chemotherapy (yes/no). Covariates included sex, payment type, verification level, injury intent, mechanism, injury place, and Injury Severity Score. We used Stata.v18 for descriptive statistics, chi-square, and logistic regression with statistical significance at p≤0.05. Results: Of the 17,940 patients, 7.9% had dementia. Seniors had higher dementia rate than younger adults (98.9% vs. 1.1%; p < 0.001). Most dementia patients had comorbidities (89.4%, p < 0.001). Chemotherapy recipients had a lower dementia rate than those untreated (8.9% vs. 91.1%; p < 0.001). In the adjusted analyses, seniors than younger adults (OR: 4.51, 95% CI: 2.38 - 8.56) and any comorbidities (OR: 1.33 ,95% CI: 1.07 - 1.65) exhibited higher odds of dementia. Notably, chemotherapy recipients had decreased odds of dementia than those untreated (OR: 0.42, 95% CI: 0.34 - 0.53). Conclusions: Metastatic cancer patients of older age and comorbidities had increased risk of dementia. Chemotherapy remarkably lowered this risk. This should guide clinicians in managing dementia risk. [Table: see text]
Investigating disparities in enrollment of patients in lung cancer clinical trials that led to FDA approval for immunotherapies between 2015 and 2023: A comparison with the US population.
Authors: Le Nhu Tuyet , Nguyen Ryan Huu-Tuan 
Published: June 2024

e23104 Background: Registrational clinical trials have led to the FDA approval of numerous immunotherapy (IO) agents in the treatment of non-small cell lung cancer (NSCLC) since 2015. Given the historical lack of adequate representation of the US population with cancer in clinical trials, we aimed to analyze disparities in race and ethnicity reporting and enrollment in lung cancer clinical trials that led to FDA-approved immunotherapies between 2015-2023. Methods: The FDA archives and database were queried to review all FDA drug approvals for IO approved to treat NSCLC between 2015 to 2023. Enrollment data were obtained from FDA labels, ClinicalTrials.gov, and corresponding journal manuscripts. The enrollment incidence ratio (EIR) and enrollment mortality ratio (EMR) were calculated as the proportion of patients of a particular race among clinical trial participants in approval studies divided by the estimated proportion of patients of that particular race diagnosed or dying of lung cancer, respectively, among the US population. Results: Among 27 trials with a total of 15,878 subjects, distribution by race shows that 77.5% were White, 16.7% Asian, 8.8% Hispanic, 1.63% Black, 0.33% American Indian Alaska Native (AIAN), and 0.07% were Native Hawaiian and Other Pacific Islander (NHOPI). 67.4% were males while 32.6% were females. The EIR for Non-Hispanic White, Non-Hispanic Black, Asian, and Hispanic patients was 0.99, 0.13, 3.56, and 0.85 respectively. The EMR for Non-Hispanic White, Non-Hispanic Black, Asian, and Hispanic patients was 0.99, 0.12, 4.23, and 0.96 respectively. Racial demographics were reported in 65% of journal manuscripts, 65% of ClinicalTrials.gov pages, and 92% of FDA labels while ethnicity demographics were reported in 0% of journal manuscripts, 42% of ClinicalTrials.gov pages, and 15% of FDA labels. Conclusions: Black, AIAN and female patients are severely underrepresented in lung cancer trials that lead to approval for IO based therapy. Asian patients were overrepresented. Less than half of the trials reported data on ethnicity. Further research is needed to see if regulatory initiatives to increase clinical trial diversity result in more equitable clinical trial enrollment in pivotal trials.
Comparing emergency department and oncology urgent care for non-emergent acute care.
Authors: Hong Arthur S. , Charania Sadaf , Bazzell Angela F. , Courtney D. Mark , Sweetenham John W. , Halm Ethan A. 
Published: June 2024

e23107 Background: Adults with cancer often visit the emergency department (ED) during treatment for commonly anticipated issues (e.g. pain, nausea). Some providers have created oncology urgent care clinics (OUCC) to manage these non-emergent issues. Evidence suggests that they are associated with lower ED use. Little is known about the care delivered at OUCCs, and how it compares to ED care. We compared visits from our OUCC to ED visits at our comprehensive cancer center. Methods: We studiedvisits from Jan 1 – June 30, 2023. To limit selection bias, we excluded ED visits if patients were referred by an outpatient clinician, including phone triage. Triage nurses document a validated Emergency Severity Index (ESI, version 4) as part of usual care in the ED, but not the OUCC. The ESI ranks high-severity (level 1 – “patient dying”; 2 – “shouldn’t wait”) to lower-severity (level 5), with the three lower levels distinguished by vital signs and clinical resources needed to stabilize a patient. Two clinicians reviewed OUCC visits and recorded ESIs. We assessed inter-rater reliability of OUCC ESI coding. We used multivariate, mixed-effects methods (visits clustered to patient) to model two outcomes: care escalation (OUCC to ED/inpatient; ED to inpatient) and length of stay (LOS). We excluded visits with ESI at the extremes (1 and 5). We adjusted for sex, age, comorbidities, cancer type and stage, date/time of arrival, and ESI. We then used marginal effects methods to report adjusted outcomes, stratified by ESI. Results: We analyzed 904 OUCC visits (580 patients) and 4,115 ED visits (2,866 patients). Over half (55.5%) of ED arrivals occurred after business hours. Median patient age was 67 (IQR 57 - 74), 48% were female, and 58% non-Hispanic white. Cancer types included 18% hematologic, 17% GI/colorectal, 12% breast, and 7% lung; 11% were advanced-stage. Unweighted inter-rater reliability for ESI was high for a subset of 164 OUCC visits (k = 0.81, 95% CI: 0.72 - 0.89). Although OUCC had a sizable portion of level 2 visits, ED had significantly higher severity. At each ESI level, adjusted rates of care escalation were significantly higher for ED than OUCC (overall aOR 5.6, 95% CI: 4.4 - 7.2), and LOS was longer for ED than OUCC (5.2 hours longer, 95% CI 4.8 – 5.6). Conclusions: The severity of OUCC visits was high, though patient self-referred ED visit severity was higher. OUCC may be more efficient than the ED for managing non-emergency care in this population. Future work should further investigate the quality of care delivered at each site, including cost of care. [Table: see text]
CGP-based IO biomarker assessment and treatment utilization across a major US health system.
Authors: Dowdell Alexa K. , Meng Ryan , Weerasinghe Roshanthi K. , Vita Ann , Bapat Bela , Hanes Douglas , Schroeder Brock , Champagne Maude , Fox John Leonard , Wong Cliff , Poon Hoifung , Bifulco Carlo B. , Piening Brian 
Published: June 2024

e23109 Background: Immune checkpoint inhibitors (IO) have become a powerful precision therapy option to treat advanced stage cancer with biomarkers such as PD-L1, tumor mutational burden (TMB), and microsatellite instability (MSI) associated with improved patient response rates. Despite this, many patients do not receive genomic testing for all IO biomarkers. Providence, a large US community health system, developed a pathologist-directed testing protocol where comprehensive genomic profiling (CGP) was routinely used at time of diagnosis for advanced cancer patients. Methods: Advanced cancer patients who received CGP (ProvSeq 523) and IHC testing for PD-L1 between 2019-2023 were included in the study. Patients were required to be treated at Providence and were assessed for presence of IO biomarkers and subsequent therapy selection. Real world data were curated from patient charts and genomic laboratory data by employing a novel natural-language processing (NLP) approach to accelerate abstraction. Results: The study included 2,502 patients (53% female, median age 68y, 83% white). Top 3 tumor types tested were lung (40%), colorectal (9%), and breast (8%). Overall, 58% (N = 1,455) of patients had presence of ≥1 IO biomarker, with 46% (N = 1,155) being PD-L1 positive, and 27% (N = 682) being TMB-H. In PD-L1 negative patients (N = 1,347; 54%), 300 (22%) were TMB-H and 18 (1%) were MSI-H. 53% (N = 767) of patients who harbored an actionable IO biomarker received IO-based therapy. Fewer patients with an IO biomarker received chemotherapy compared to patients without an IO biomarker (23% vs 35%, p < 0.001). Patients who possessed ≥2 IO biomarkers received an IO precision therapy 68% of the time vs 47% in patients with 1 IO biomarker (p < 0.001). In PD-L1 negative patients, 26% (N = 78) of TMB-H patients received IO monotherapy compared to 5% (N = 49) of TMB-L patients. Conclusions: IO biomarker presence is associated with increased precision therapy use. CGP identified many TMB-H patients for IO monotherapy that would have been missed with PD-L1 testing alone. More than half of patients eligible for IO therapy don’t receive it; ongoing analyses will evaluate the impact of pathology-directed reflex testing on IO as well as targeted therapy approaches. [Table: see text]
Mapping disparities in head and neck cancer care: Geospatial analysis of social vulnerability and healthcare access in the US.
Authors: Black Christopher M. , Zheng Dandan , Goodnight Bradley , Habila Magdiel , Merchant Sanjay , Cassese Marie , Fortman Alexander , Walbert Harold , Sieling Fred , Hanna Glenn J. 
Published: June 2024

e23112 Background: Ensuring equitable access to head and neck (H&N) cancer care across the US is vital for optimal patient outcomes. This study explores the impact of social vulnerability on disparities in access to H&N multidisciplinary specialist care by US region and metro status. Methods: Oncologists and a subset of H&N cancer specialist practice locations were extracted from the National Provider Index, American Society of Clinical Oncology, and US News and World Report. Travel time using the fastest transportation mode from population-weighted county centroids to the nearest H&N cancer specialist (surgical, radiation, or medical oncologist) was computed using Travel Time API. Cancer data were obtained from United States Cancer Statistics and Surveillance, Epidemiology, and End Results (SEER). Regression analysis assessed impact of aspects of social vulnerability from the Social Vulnerability Index (SVI) on travel time. A disparity index incorporating travel time, county-level H&N cancer incidence, and SVI was developed to quantify disparities at the county-level. Results: In total, 18,241 medical, 6,387 radiation, and 2,564 surgical oncologists were identified, of which 346 medical, 308 radiation, and 453 surgical oncologists self-identified as H&N specialists. Regression analysis indicated that low household income and lack of insurance within counties significantly increased travel time ( p < .001) after controlling for US region, metro status, cancer rate, and other county-level factors. The disparity index identified counties with highest and lowest disparity (Table 1). Conclusions: Key findings highlight specific counties with higher vulnerability, primarily rural counties in the West and Southeast, and underscores the influence of social vulnerability on access to care. After accounting for US region and metro status, aspects of social vulnerability still predict travel time, with low household income and lack of insurance being the most impactful. Identified disparities in care may provide targets for interventions and policies aimed at reducing access inequalities, such as outreach programs and allocation of resources to underserved areas. [Table: see text]
Access to cancer center information for patients with limited English proficiency from NCI Cancer Center websites.
Authors: Fuchs Jeffrey William , Fuchs Joseph Robert , Theros Jonathan S , Liu Yingzhe , Sun Zequn , Mohindra Nisha Anjali 
Published: June 2024

e23124 Background: Patients with Limited English Proficiency (LEP) can experience health disparities in cancer care and clinical trial participation. This study sought to assess the availability of information on interpreter services, clinical trials, and second opinions from National Cancer Institute – Designated Cancer Center (NCI-DCC) websites for patients with LEP. Methods: The public facing websites of all 65 adult NCI-DCCs were reviewed from January 1, 2023 to May 15, 2023 to assess availability of English and translated, non-English information on interpreter services, second opinion programs, and clinical trials. Data abstraction was conducted through predefined criteria for website inspection and search bars. Three authors independently abstracted websites for content, with constant comparison until consensus was achieved. Chi-square tests were used to ascertain any significant association between the proportion of LEP populations served by the centers ( > 5%) and their likelihood to provide translated information. Results: 92.3% of NCI-DCCs and their affiliated flagships hospitals provide information on interpreter services for patients with LEP. This information was translated into a non-English language approximately half of the time. All NCI-DCC center webpages provide information on clinical trials and 38.5% provide information regarding second opinions. There was no difference in the availability of translated information on interpreter services or second opinion programs based on percentage of LEP population. However, there was an association between higher LEP population and the provision of translated clinical trial pages. Conclusions: The majority of NCI-DCCs provide information on their webpages related to interpreter services and clinical trials. Half of these centers provide this information in a non-English language and there was an association between higher percentage of LEP populations in the NCI-DCC state and translated clinical trial pages. Future work should identify optimal methods to provide cancer related information to patients with LEP with the goal of improving clinical trial participation for LEP populations. [Table: see text]
Oncofertility: The unmet need.
Authors: Venkitaraman Balasubramanian 
Published: June 2024

e23143 Background: Breast cancer incidence has been increasing across the globe and it has become most common cancer among women in Indian population also. The age trend of breast cancer incidence has shown change, with increasing number of women in the young age group( < 35 years) developing breast cancer.With increasing incidence of breast cancer among young women, the question of fertility in these young women becomes a significant issue. Most of these patients are in a state of shock when they are detectedwith cancer. It becomes the utmost responsibility of the treating oncologist to discuss about fertility issueswith the patient. This study was done to determine the prevalent knowledge, practice and attitude among oncologist across various parts in India with respect to fertility issues. Methods: We performed an online survey among oncologist spread across the country. The survey included questions aimed to identify their knowledge and attitude towards fertility preservation in young breast cancer patients and what they actually practice. Also demography details of the oncologist were recorded to identity and socioeconomic or cultural variations affecting their practice behaviour. Their response was graded and analysis done using SPSS software. Results: A total of 123 oncologists had completed the survey. Among the responders majority were surgical oncologist (68.3%) followed by medical and radiation oncologist with majority doing Institution based practice. Most of the oncologists were aware of the literature available for onco fertility discussion with patient. 84.91%responders had the knowledge that this discussion should be initiated at the time of diagnosis of disease. There were no significant disparity among respondents with respect to location and site of practice in terms of knowledge 88.68% were comfortable in discussing these issues with the patients; however, majority of responders felt that very few patients came out to discuss options of onco fertility (less than 25% of patients). Most of the responders were aware of the facilities available for appropriate referrals In practice, 63.4% said they had offered information, however patient has declined to take any further step . 22.76% of responders had actually successfully referred at least one patient for fertility consultation. Conclusions: There seems to be a positive trend in terms of fertility conservation among oncologist, however study has identified a lack of willingness among young Indian breast cancer patients to seek such treatments.
Adherence and persistence of encorafenib in combination with cetuximab among patients with BRAF metastatic CRC in the United States (US) based on two claims databases.
Authors: Parikh Aparna Raj , Vieira Maria Cecilia , Silver Michelle , Rava Andrew , Rau Reina , Li Benjamin 
Published: June 2024

e23146 Background: The BRAF V600E mutation (BRAF-m) occurs in approximately 7% of patients with metastatic CRC (mCRC). Encorafenib (enco) in combination with cetuximab (cetux) was approved in April 2020 as the first targeted regimen for the treatment of adult patients with mCRC with BRAF-m. The purpose of this study is to analyze the post-approval real-world persistence and adherence to treatment with enco in combination with cetux or with panitumumab (pani), an alternative EGFR, in mCRC, based on two claims databases in the US. Methods: This was a retrospective cohort study in the IQVIA PharMetrics Plus database and the Merative MarketScan Commercial Database (2013-2022). Adults ≥18 years old with ≥1 claim for enco (first claim for enco on/after its date of approval in April 2020) with concurrent EGFR (cetux or pani), ≥2 ICD-9/10 codes for malignancy of the colon or rectum ≥30 days apart in the 1 year before index date, and ≥1 day of pharmacy and medical continuous enrollment during the index date were included. Patients were excluded if they had a record of melanoma or non-small cell lung cancer during the year before index date, were enrolled in a clinical trial any time after the CRC diagnosis date or did not have a treatment regimen starting on or after CRC diagnosis date (-14 days). Index date was the date of first treatment of enco + EGFR during the identification period (4/1/2020-3/31/2022). Patient demographics and disease characteristics were assessed at baseline, adherence (measured as at least 80% of days covered) and persistence (measured as time to discontinuation by Kaplan-Meier method) were estimated during the follow-up period. Results: 205 patients were included. Median (Q1 [1st quartile], Q3 [3rd quartile]) age at index was 59 (50, 64) years and 51.7% were female. Metastases were present in 3 or more sites in 62.9% of the patients, in 1 or 2 sites in 35.6%. The 2011 Modified Quan Charlson Comorbidity Index was 0 for 44.9% of the patients, 1-2 for 38.5%, and 3 or more for 16.6%. Most patients received cetux as their EGFR combined with enco (76.1%). Adherence to enco + EGFR was high (87.8%); enco + cetux vs. enco + pani: 89.7% vs. 82.6%. Median (Q1, Q3) proportion of time on cetux while on enco was 87% (78%, 95%) and median (Q1, Q3) proportion of time on pani while on enco was 85% (71%, 91%). Median (95% confidence interval) time to enco regimen discontinuation during follow-up was 6.1 (5.3–7.7) months. Conclusions: This up-to-date study provides current real-world evidence on the use of enco + EGFR in mCRC BRAF-m patients in the US. The results show high levels of adherence to the treatment, suggesting high tolerability to encorafenib, and persistence consistent with clinical trial evidence.